Header Logo

Connection

CHRISTIE BALLANTYNE to Adult

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Adult.
CHRISTIE BALLANTYNE
Connection Strength
1.942
Adult
  1. Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
    View in: PubMed
    Score: 0.057
  2. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024 Jul 01; 9(7):620-630.
    View in: PubMed
    Score: 0.055
  3. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
    View in: PubMed
    Score: 0.055
  4. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
    View in: PubMed
    Score: 0.050
  5. Severe hypercholesterolemia in a patient with very low albumin and normal renal function. J Clin Lipidol. 2023 Jan-Feb; 17(1):64-67.
    View in: PubMed
    Score: 0.049
  6. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 01; 280:109-117.
    View in: PubMed
    Score: 0.037
  7. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.034
  8. Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. J Clin Endocrinol Metab. 2016 11; 101(11):4195-4204.
    View in: PubMed
    Score: 0.032
  9. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.032
  10. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15; 117(12):1928-33.
    View in: PubMed
    Score: 0.031
  11. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun; 10(3):556-67.
    View in: PubMed
    Score: 0.031
  12. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol. 2016 May-Jun; 10(3):497-504.e4.
    View in: PubMed
    Score: 0.030
  13. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.029
  14. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun; 9(3):377-83.
    View in: PubMed
    Score: 0.028
  15. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.026
  16. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.024
  17. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
    View in: PubMed
    Score: 0.023
  18. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J Clin Lipidol. 2012 May-Jun; 6(3):235-43.
    View in: PubMed
    Score: 0.023
  19. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.023
  20. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.023
  21. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.022
  22. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
    View in: PubMed
    Score: 0.019
  23. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
    View in: PubMed
    Score: 0.018
  24. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.018
  25. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.017
  26. Eotaxin and obesity. J Clin Endocrinol Metab. 2006 Jan; 91(1):256-61.
    View in: PubMed
    Score: 0.015
  27. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 Mar; 149(3):464-73.
    View in: PubMed
    Score: 0.014
  28. Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
    View in: PubMed
    Score: 0.014
  29. Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
    View in: PubMed
    Score: 0.014
  30. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses. Eur J Endocrinol. 2024 Oct 29; 191(5):523-534.
    View in: PubMed
    Score: 0.014
  31. Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
    View in: PubMed
    Score: 0.014
  32. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
    View in: PubMed
    Score: 0.014
  33. Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
    View in: PubMed
    Score: 0.014
  34. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004 Sep; 6(5):353-62.
    View in: PubMed
    Score: 0.014
  35. Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study. Eur J Prev Cardiol. 2024 Jul 23; 31(9):1123-1131.
    View in: PubMed
    Score: 0.014
  36. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
    View in: PubMed
    Score: 0.014
  37. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
    View in: PubMed
    Score: 0.014
  38. Individual and Joint Associations of High-Sensitivity Troponin I and High-Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study. J Am Heart Assoc. 2024 Jul 02; 13(13):e034549.
    View in: PubMed
    Score: 0.014
  39. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 05 16; 390(19):1781-1792.
    View in: PubMed
    Score: 0.014
  40. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
    View in: PubMed
    Score: 0.013
  41. Trends in sleep apnea and heart failure related mortality in the United States from 1999 to 2019. Curr Probl Cardiol. 2024 Feb; 49(2):102342.
    View in: PubMed
    Score: 0.013
  42. Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020. JAMA Cardiol. 2023 12 01; 8(12):1185-1187.
    View in: PubMed
    Score: 0.013
  43. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
    View in: PubMed
    Score: 0.013
  44. Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses. Ann Intern Med. 2023 09; 176(9):1221-1234.
    View in: PubMed
    Score: 0.013
  45. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
    View in: PubMed
    Score: 0.013
  46. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.013
  47. Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 11; 11(21):e026762.
    View in: PubMed
    Score: 0.012
  48. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
    View in: PubMed
    Score: 0.012
  49. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
    View in: PubMed
    Score: 0.012
  50. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.012
  51. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021 11 07; 42(42):4324-4332.
    View in: PubMed
    Score: 0.011
  52. Technology-Assisted Self-Selection of Candidates for Nonprescription Statin?Therapy. J Am Coll Cardiol. 2021 09 14; 78(11):1114-1123.
    View in: PubMed
    Score: 0.011
  53. Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 09 07; 10(17):e020890.
    View in: PubMed
    Score: 0.011
  54. Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
    View in: PubMed
    Score: 0.011
  55. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.011
  56. Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. Am J Prev Med. 2021 10; 61(4):492-500.
    View in: PubMed
    Score: 0.011
  57. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.011
  58. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.011
  59. Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia. Am J Med. 2021 08; 134(8):992-1001.e4.
    View in: PubMed
    Score: 0.011
  60. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.011
  61. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001 Feb; 23(2):177-92.
    View in: PubMed
    Score: 0.011
  62. Biomarker-Based Risk Prediction of Incident Heart?Failure in Pre-Diabetes and?Diabetes. JACC Heart Fail. 2021 03; 9(3):215-223.
    View in: PubMed
    Score: 0.011
  63. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.011
  64. Deficiency of Stat1 in CD11c+ Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet. Diabetes. 2021 03; 70(3):720-732.
    View in: PubMed
    Score: 0.011
  65. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.011
  66. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
    View in: PubMed
    Score: 0.011
  67. Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. Popul Health Manag. 2021 06; 24(3):414-415.
    View in: PubMed
    Score: 0.011
  68. High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
    View in: PubMed
    Score: 0.011
  69. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.011
  70. Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
    View in: PubMed
    Score: 0.010
  71. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020 08 18; 142(7):657-669.
    View in: PubMed
    Score: 0.010
  72. Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. Am J Med. 2020 11; 133(11):1293-1301.e1.
    View in: PubMed
    Score: 0.010
  73. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med. 2000 May 08; 160(9):1361-9.
    View in: PubMed
    Score: 0.010
  74. Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
    View in: PubMed
    Score: 0.010
  75. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
    View in: PubMed
    Score: 0.010
  76. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000 Jan; 35(1):89-95.
    View in: PubMed
    Score: 0.010
  77. Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circ Cardiovasc Imaging. 2019 12; 12(12):e009535.
    View in: PubMed
    Score: 0.010
  78. Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nat Commun. 2019 Nov 12; 10(1):5121.
    View in: PubMed
    Score: 0.010
  79. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019 12 17; 140(25):2076-2088.
    View in: PubMed
    Score: 0.010
  80. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17?180 Individuals. Circ Res. 2019 09 27; 125(8):773-782.
    View in: PubMed
    Score: 0.010
  81. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.010
  82. Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
    View in: PubMed
    Score: 0.010
  83. Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019 Apr; 51(4):636-648.
    View in: PubMed
    Score: 0.010
  84. Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath. 2019 Dec; 23(4):1107-1114.
    View in: PubMed
    Score: 0.009
  85. Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. JAMA Cardiol. 2019 01 01; 4(1):51-58.
    View in: PubMed
    Score: 0.009
  86. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.009
  87. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018 11 01; 103(5):691-706.
    View in: PubMed
    Score: 0.009
  88. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.009
  89. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
    View in: PubMed
    Score: 0.009
  90. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998 May; 18(5):723-31.
    View in: PubMed
    Score: 0.009
  91. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.009
  92. Weight History and Subclinical Myocardial Damage. Clin Chem. 2018 01; 64(1):201-209.
    View in: PubMed
    Score: 0.009
  93. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
    View in: PubMed
    Score: 0.009
  94. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017 05 30; 135(22):2119-2132.
    View in: PubMed
    Score: 0.008
  95. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.008
  96. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.008
  97. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
    View in: PubMed
    Score: 0.008
  98. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.008
  99. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
    View in: PubMed
    Score: 0.008
  100. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
    View in: PubMed
    Score: 0.008
  101. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
    View in: PubMed
    Score: 0.008
  102. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.008
  103. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.008
  104. Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016 Jun; 49(9):657-662.
    View in: PubMed
    Score: 0.008
  105. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.008
  106. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.008
  107. Postprandial effects on arterial stiffness parameters in healthy young adults. Vasc Med. 2015 Dec; 20(6):501-8.
    View in: PubMed
    Score: 0.007
  108. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27; 371(22):2072-82.
    View in: PubMed
    Score: 0.007
  109. Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
    View in: PubMed
    Score: 0.007
  110. Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
    View in: PubMed
    Score: 0.007
  111. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.
    View in: PubMed
    Score: 0.007
  112. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
    View in: PubMed
    Score: 0.007
  113. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014 Apr; 35(15):960-8.
    View in: PubMed
    Score: 0.007
  114. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014 Apr 15; 63(14):1441-8.
    View in: PubMed
    Score: 0.007
  115. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014 Feb 06; 94(2):233-45.
    View in: PubMed
    Score: 0.007
  116. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS One. 2013; 8(12):e81615.
    View in: PubMed
    Score: 0.007
  117. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
    View in: PubMed
    Score: 0.006
  118. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol. 2013 Nov-Dec; 7(6):661-70.
    View in: PubMed
    Score: 0.006
  119. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
    View in: PubMed
    Score: 0.006
  120. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb; 13(1):37-46.
    View in: PubMed
    Score: 0.006
  121. A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J Clin Lipidol. 2013 Jan-Feb; 7(1):82-7.
    View in: PubMed
    Score: 0.006
  122. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
    View in: PubMed
    Score: 0.006
  123. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012 Jul; 27(7):2839-47.
    View in: PubMed
    Score: 0.006
  124. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.006
  125. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol. 2012 Jan-Feb; 6(1):50-7.
    View in: PubMed
    Score: 0.006
  126. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
    View in: PubMed
    Score: 0.006
  127. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011 Sep 11; 43(10):940-7.
    View in: PubMed
    Score: 0.006
  128. Segmental analysis of carotid arterial strain using speckle-tracking. J Am Soc Echocardiogr. 2011 Nov; 24(11):1276-1284.e5.
    View in: PubMed
    Score: 0.006
  129. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
    View in: PubMed
    Score: 0.006
  130. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.006
  131. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul; 96(7):2236-47.
    View in: PubMed
    Score: 0.006
  132. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8.
    View in: PubMed
    Score: 0.006
  133. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
    View in: PubMed
    Score: 0.006
  134. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
    View in: PubMed
    Score: 0.005
  135. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.005
  136. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
    View in: PubMed
    Score: 0.005
  137. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 07; 262(1):53-6.
    View in: PubMed
    Score: 0.005
  138. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord. 2009 Jan 27; 9:3.
    View in: PubMed
    Score: 0.005
  139. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
    View in: PubMed
    Score: 0.005
  140. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008 Nov; 156(5):1002.e1-1002.e7.
    View in: PubMed
    Score: 0.005
  141. APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet. 2008 Jul 01; 17(13):2039-46.
    View in: PubMed
    Score: 0.004
  142. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007 Nov 01; 100(9):1387-96.
    View in: PubMed
    Score: 0.004
  143. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
    View in: PubMed
    Score: 0.004
  144. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
    View in: PubMed
    Score: 0.004
  145. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials. 2006 Dec; 27(6):518-30.
    View in: PubMed
    Score: 0.004
  146. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
    View in: PubMed
    Score: 0.004
  147. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.004
  148. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.003
  149. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.003
  150. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003 Apr 29; 107(16):2102-8.
    View in: PubMed
    Score: 0.003
  151. Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thromb Res. 2003; 111(3):171-7.
    View in: PubMed
    Score: 0.003
  152. Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin Chem. 2002 Nov; 48(11):1913-8.
    View in: PubMed
    Score: 0.003
  153. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug; 43(8):1170-80.
    View in: PubMed
    Score: 0.003
  154. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
    View in: PubMed
    Score: 0.003
  155. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
    View in: PubMed
    Score: 0.003
  156. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
    View in: PubMed
    Score: 0.003
  157. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
    View in: PubMed
    Score: 0.002
  158. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med. 1999 May 10; 159(9):981-7.
    View in: PubMed
    Score: 0.002
  159. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 Apr; 143(2):285-97.
    View in: PubMed
    Score: 0.002
  160. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
    View in: PubMed
    Score: 0.002
  161. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
    View in: PubMed
    Score: 0.002
  162. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc. 1993 Feb; 25(1 Pt 1):233-6.
    View in: PubMed
    Score: 0.002
  163. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991 Feb 01; 67(4):243-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.